Table 1.
Primers used in this study.
| Primersa | Sequence (5′–3′)b | Product size (bp) | Use |
|---|---|---|---|
| 1F | GGTTTAAACTAGCCGCCAGCGGCTTGACC (Dra I) | 1920 | Nsp9 gene amplification |
| 1R | GGAAGCTTCTCATGATTGGACCTGAGTTT (HindIII) | ||
| 2F | GGCATATGATGTCGAGTTATTCAAGTGAC (Nde I) | 1845 | DDX5 gene amplification |
| 2R | GCGGATCCTTATTGAGAATATCCTGTTGG (BamH I) | ||
| 3F | GGTTTAAACTAGCCGCCAGCGGCTTGACC (Sal I) | pCMV-HA-Nsp9 construction | |
| 3R | GGAAGCTTCTCATGATTGGACCTGAGTTT (Kpn I) | ||
| 4F | GGCATATGATGTCGAGTTATTCAAGTGAC (Sal I) | pCMV-Myc-DDX5 construction | |
| 4R | GCGGATCCTTATTGAGAATATCCTGTTGG (Kpn I) | ||
| 5F | GCGTTTAAACCTAGCCGCCAGCGGCTTGACC (Pme I) | pWPXL-Nsp9 construction | |
| 5R | GCACGCGTCTCATGATTGGACCTGAGTTT (Mlu I) | ||
| 6F | GCGTTTAAACATGTCGAGTTATTCAAGTGAC (Pme I) | pWPXL-DDX5 construction | |
| 6R | GCACGCGTTTATTGAGAATATCCTGTTGG (Mlu I) | ||
| 7F | CGGTCGACCCTAGCCGCCAGCGGCTTGACC (Sal I) | pCMV-HA-Nsp9-N construction | |
| 7R | CGGCGGCCGCTAGGACCGGGGCTTGTAGCTC (Not I) | ||
| 8F | CCGTCGACGGCAGGTGCCTTGAAGCTGAT (Sal I) | pCMV-HA-Nsp9-C construction | |
| 8R | CCGCGGCCGCCTCATGATTGGACCTGAGTTT (Not I) | ||
| 9F | GCAGATCTCCATGTCGAGTTATTCAAGTGAC (Bgl II) | pCMV-Myc-DDX5-N construction | |
| 9R | GCGCGGCCGCGGTACTGCGGGCAGTTCTTCC (Not I) | ||
| 10F | GCGAATTCGGAAAACAGGCACAGCATACACT (EcoR I) | pCMV-Myc-DDX5-C construction | |
| 10R | GCGGTACCTTATTGAGAATATCCTGTTGGC (Kpn I) |
a
F denotes forward PCR primer; R denotes reverse PCR primer.
b
Restriction sites are underlined.